» Articles » PMID: 34830256

The Role of Cannabinoids in Bone Metabolism: A New Perspective for Bone Disorders

Overview
Journal Int J Mol Sci
Publisher MDPI
Date 2021 Nov 27
PMID 34830256
Citations 6
Authors
Affiliations
Soon will be listed here.
Abstract

Novel interest has arisen in recent years regarding bone, which is a very complex and dynamic tissue deputed to several functions ranging from mechanical and protective support to hematopoiesis and calcium homeostasis maintenance. In order to address these tasks, a very refined, continuous remodeling process needs to occur involving the coordinated action of different types of bone cells: osteoblasts (OBs), which have the capacity to produce newly formed bone, and osteoclasts (OCs), which can remove old bone. Bone remodeling is a highly regulated process that requires many hormones and messenger molecules, both at the systemic and the local level. The whole picture is still not fully understood, and the role of novel actors, such as the components of the endocannabinoids system (ECS), including endogenous cannabinoid ligands (ECs), cannabinoid receptors (CBRs), and the enzymes responsible for endogenous ligand synthesis and breakdown, is extremely intriguing. This article reviews the connection between the ECS and skeletal health, supporting the potential use of cannabinoid receptor ligands for the treatment of bone diseases associated with accelerated osteoclastic bone resorption, including osteoporosis and bone metastasis.

Citing Articles

The Presence of the Endocannabinoid System in an In Vitro Model of Gorham-Stout Disease and Its Possible Role in the Pathogenesis.

Aurilia C, Palmini G, Donati S, Falsetti I, Galli G, Margheriti L Int J Mol Sci. 2025; 26(3).

PMID: 39940911 PMC: 11818735. DOI: 10.3390/ijms26031143.


Shared genetic architecture highlights the bidirectional association between major depressive disorder and fracture risk.

Zhao P, Ying Z, Yuan C, Zhang H, Dong A, Tao J Gen Psychiatr. 2024; 37(3):e101418.

PMID: 38737893 PMC: 11086190. DOI: 10.1136/gpsych-2023-101418.


Correlation analysis of positron emission tomography/computed tomography-magnetic resonance imaging of cannabinoid type 1 receptor in the lumbar spine and brain of aged osteoporosis female cynomolgus monkeys.

Hou L, Zhang H, Li Y, Zhu H, Liao K, Guo B Quant Imaging Med Surg. 2023; 13(12):7924-7935.

PMID: 38106237 PMC: 10722013. DOI: 10.21037/qims-23-118.


CB2 regulates oxidative stress and osteoclastogenesis through NOX1-dependent signaling pathway in titanium particle-induced osteolysis.

Tao H, Li X, Chu M, Wang Q, Li P, Han Q Cell Death Discov. 2023; 9(1):461.

PMID: 38104087 PMC: 10725463. DOI: 10.1038/s41420-023-01761-y.


Interoceptive regulation of skeletal tissue homeostasis and repair.

Xiao Y, Han C, Wang Y, Zhang X, Bao R, Li Y Bone Res. 2023; 11(1):48.

PMID: 37669953 PMC: 10480189. DOI: 10.1038/s41413-023-00285-6.


References
1.
Koal T, Deters M, Casetta B, Kaever V . Simultaneous determination of four immunosuppressants by means of high speed and robust on-line solid phase extraction-high performance liquid chromatography-tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. 2004; 805(2):215-22. DOI: 10.1016/j.jchromb.2004.02.040. View

2.
Karsak M, Malkin I, Toliat M, Kubisch C, Nurnberg P, Zimmer A . The cannabinoid receptor type 2 (CNR2) gene is associated with hand bone strength phenotypes in an ethnically homogeneous family sample. Hum Genet. 2009; 126(5):629-36. DOI: 10.1007/s00439-009-0708-8. View

3.
Karsak M, Cohen-Solal M, Freudenberg J, Ostertag A, Morieux C, Kornak U . Cannabinoid receptor type 2 gene is associated with human osteoporosis. Hum Mol Genet. 2005; 14(22):3389-96. DOI: 10.1093/hmg/ddi370. View

4.
Rayman N, Lam K, Laman J, Simons P, Lowenberg B, Sonneveld P . Distinct expression profiles of the peripheral cannabinoid receptor in lymphoid tissues depending on receptor activation status. J Immunol. 2004; 172(4):2111-7. DOI: 10.4049/jimmunol.172.4.2111. View

5.
Sunyecz J . The use of calcium and vitamin D in the management of osteoporosis. Ther Clin Risk Manag. 2009; 4(4):827-36. PMC: 2621390. DOI: 10.2147/tcrm.s3552. View